Xenetic Biosciences Expands Management Team with Key Appointment of Jeffrey F. Eisenberg as Chief Operating Officer
Xenetic Biosciences to Present at the LD Micro 2016 Annual Conference
Xenetic Biosciences to Host Quarterly Update Conference Call and Webcast
Xenetic Biosciences Appoints Edward J. Benz, Jr., M.D., Former Dana-Farber CEO, to its Board of Directors
Xenetic Biosciences Reports Third Quarter Financial Results and Provides Business Update
Xenetic Biosciences Announces the Closing of its $10M Public Offering
Xenetic Biosciences Announces Nasdaq Listing of its Common Stock and Pricing of $10M Public Offering
Xenetic Biosciences Reports Positive Topline Data from Third Cohort of Phase 2 Dose-Escalation Trial of ErepoXen® for Anemia
Xenetic Biosciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference
